Introduction

Ethics and Institutional Oversight in biotechnology concern the principles, procedures and public authorities responsible for ensuring that scientific research respects human dignity, informed consent, privacy, safety and social responsibility. In China, these requirements are particularly important in genetic engineering, stem-cell research, clinical trials, human genetic resources and emerging biomedical technologies. The regulatory framework seeks to balance scientific innovation with biosecurity, public health and protection of research participants.

Legal and Regulatory Framework

1. Biosecurity Law of China

The Biosecurity Law of the People’s Republic of China, effective from 15 April 2021, provides a central statutory foundation for biotechnology ethics and institutional responsibility. Article 34 requires biotechnology research, development and application to follow ethical principles and prohibits activities that threaten public health, living resources or biodiversity. Article 35 places responsibility on research institutions to manage their activities, prevent biosecurity risks, provide training and conduct inspections and reporting.

Article 36 establishes classified management of biotechnology research and development. Articles 55–57 address ethical principles and regulatory requirements concerning Chinese human genetic resources and related information. These provisions demonstrate that ethical oversight is connected with both individual protection and broader public interests. <Cite refs={["turn461421search0","turn461421search7"]}/>

2. Measures for Ethical Review of Life Science and Medical Research Involving Humans

China introduced the Measures for Ethical Review of Life Science and Medical Research Involving Humans in 2023. These measures establish requirements for ethical review of covered research involving human participants, biological samples or identifiable personal information.

Research institutions must establish or use appropriate ethics-review arrangements, assess risks and benefits, protect participants’ rights and ensure that informed consent is obtained where required. Ethical committees should examine research protocols independently and monitor compliance with approved conditions. Changes to research design or emerging safety concerns may require further review.

3. Human Genetic Resources and Personal Information

China’s Regulations on the Administration of Human Genetic Resources, together with the Biosecurity Law and applicable personal-information legislation, govern the collection, use, preservation and transfer of regulated genetic resources and information. The applicable requirements depend on the research activity, the parties involved and whether materials or information cross national borders.

Researchers must consider informed consent, confidentiality, permissible research purposes and relevant approval, filing or security-review requirements. Institutional oversight is especially important in international collaborations because ethical permission alone does not necessarily satisfy every regulatory requirement.

Institutional Oversight Mechanisms

1. Research Ethics Committees

Research ethics committees review study design, participant selection, consent procedures, risk management and the protection of vulnerable participants. Their purpose is to ensure that scientific value does not override fundamental ethical safeguards. Proper records, conflict-of-interest disclosure and continuing monitoring help establish accountability.

2. Governmental Supervision

Different government authorities oversee biosecurity, health research, pharmaceutical products, human genetic resources and data protection according to their statutory responsibilities. This distributed system requires coordination between research institutions and competent regulators.

3. Accountability and Enforcement

Ethical violations may result in suspension of research, administrative penalties, professional consequences, civil liability or criminal proceedings, depending on the conduct and applicable law. Institutional approval does not excuse unlawful conduct, and researchers remain responsible for compliance with relevant legal requirements.Relevant Case Laws

1. He Jiankui and Others — Shenzhen Nanshan District People’s Court (2019)

On 30 December 2019, the Nanshan District People’s Court convicted He Jiankui and two collaborators of illegal medical practice involving reproductive human-embryo gene editing. He received three years’ imprisonment and a fine of RMB 3 million; the other defendants received lesser sentences. The court found that the researchers had violated relevant regulations and medical ethics, used falsified ethical-review documents and undertaken reproductive interventions without establishing safety and effectiveness.

中华人民共和国最高人民法院

+1

Legal significance: This case demonstrates that scientific ambition and institutional participation cannot replace genuine ethical approval, professional qualifications or legal authorisation. It remains a major example of criminal accountability for serious misconduct in human genetic research.

2. WuXi AppTec Human Genetic Resources Administrative Penalty (2016)

China’s Ministry of Science and Technology imposed an administrative penalty on Suzhou WuXi AppTec New Drug Development Co., Ltd. after finding that human blood-serum samples had been transferred outside China under an inaccurate description without the required authorisation. The authority ordered corrective measures and imposed sanctions concerning the materials and relevant activities.

Oxford Academic

+1

Legal significance: Although this was an administrative enforcement decision rather than a court judgment, it illustrates the importance of institutional supervision, accurate research documentation and compliance with requirements governing human genetic resources.

3. Human Genetic Resources Governance under the Biosecurity Law

Articles 55–57 of China’s Biosecurity Law establish ethical and regulatory safeguards for collecting, preserving, using and providing human genetic resources and related information. Article 79 provides penalties for specified unauthorised activities.

National People's Congress

+1

These are statutory provisions, not case-law precedents. They demonstrate how institutional ethical duties are supported by administrative enforcement and legal liability.

Challenges and Institutional Reforms

China’s framework faces challenges involving committee independence, conflicts of interest, inconsistent review practices, emerging technologies and cross-border research. Effective oversight requires clear institutional responsibilities, transparent review records, appropriate training and continuing monitoring. Ethics committees should have sufficient independence to reject scientifically promising projects when risks or consent arrangements are unacceptable.

International collaborations also require coordination between ethical review, data protection, biosecurity and intellectual-property obligations. Public engagement and transparent communication can strengthen confidence in scientific institutions, particularly when research may have consequences for future generations.

Conclusion

Ethics and institutional oversight form essential parts of China’s biotechnology regulatory system. The Biosecurity Law, the 2023 ethical-review measures and human genetic resources regulations establish safeguards for research participants, biological materials and public interests. The He Jiankui judgment illustrates the consequences of serious violations, while administrative enforcement demonstrates the importance of institutional compliance. A credible oversight system requires independent ethical review, informed consent, proportionate enforcement and continuing accountability so that biotechnology advances within lawful and ethically defensible boundaries.